Sequence 24 from Patent US 20060122119
General Information
DCTPep ID DCTPep01279
Peptide Name Sequence 24 from Patent US 20060122119
Sequence QVPLDCVLYR
Sequence Length 10
PubChem CID Not available
Origin Homo sapiens
Type Native peptide
Classification
ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure Not available
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Not available
Disulfide/Other Bond Not available
N-terminal Modification Not available
C-terminal Modification Not available
Other Modification None
Chiral L
Physicochemical Information
Formula C54H88N14O15S1
Absent amino acids AEFGHIKMNSTW
Theoretical pI 5.83
Acidic residues 1
Basic residues 1
Polar residues 2
Molecular weight (Average) 1205.44
Molecular weight (Monoisotopic) 1204.63
Common amino acids LV
Net charge 0
Instability index (II) -3.73
Aliphatic index 136.00
Grand average of hydropathicity (GRAVY) 0.410
Half Life
0.8 hours (mammalian reticulocytes, in vitro).
10 min (yeast, in vivo).
10 hours (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 1490
Abs 0.1% (=1 g/l) 1.236, assuming all pairs of Cys residues form cystines
Ext. coefficient 1490
Abs 0.1% (=1 g/l) 1.236, assuming all Cys residues are reduced
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2006/0122119 A1
Patent Title Peptides for use in antitumor immunotherapy.
Other Iinformation Granted Patent Family: 10s / 10ex; Family Jurisdictions: CA, AU, FR, WO, US, EP, JP; Legal Status: Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002
Other Published ID CA2477762A1 EP1481009A2 WO2003074565A2 WO2003074565A3